Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCQ | Q04759 | 7/20 | 0.43 |
| ▸ | GSK3A | P49840 | 2/20 | 0.42 |
| ▸ | GSK3B | P49841 | 2/20 | 0.42 |
| ▸ | ACACB | O00763 | 4/20 | 0.40 |
| ▸ | CDK2 | P24941 | 2/20 | 0.39 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.39 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.39 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.39 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | MAPK8 | P45983 | 3/20 | 0.36 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.36 |
| ▸ | MERTK | Q12866 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29802533 | 0.91 | PRKCQ (0.42) | PRKCQGSK3AGSK3BACACBCDK2 | |
| SCHEMBL19665539 | 0.87 | GSK3A (0.48) | PRKCQGSK3AGSK3BACACBCDK2 | |
| SCHEMBL29802475 | 0.85 | ACACB (0.42) | ACACBCDK2CCNE2CCNA2CCNE1 | |
| SCHEMBL28644736 | 0.81 | STK17B (0.46) | CDK2CCNE2CCNA2CCNE1CCNA1 | |
| SCHEMBL29802473 | 0.81 | STK17B (0.46) | CDK2CCNE2CCNA2CCNE1CCNA1 | |
| SCHEMBL19665528 | 0.81 | PRKCQ (0.46) | PRKCQGSK3AGSK3BCDK2MEN1 | |
| SCHEMBL29802572 | 0.79 | PRKCQ (0.43) | PRKCQGSK3AGSK3BCDK2MEN1 | |
| SCHEMBL27582230 | 0.78 | GSK3A (0.42) | GSK3AGSK3BMEN1KMT2A | |
| SCHEMBL19665741 | 0.78 | GSK3A (0.47) | PRKCQGSK3AGSK3BACACBCDK2 | |
| SCHEMBL29802703 | 0.76 | MAPK8 (0.42) | ACACBMAPK8MAPK9MERTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3464287-B1 | ANIMAL AND HUMAN ANTI-MALARIAL AGENTS | CELGENE CORP (US) | 2022-06-08 | — | — | EP | disclosed |
| US-11344554-B2 | Animal and human anti-malarial agents | CELGENE CORPORATION (US) | 2022-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11344554-B2 | Animal and human anti-malarial agents | HPRT1, UMPS, PNP | PRKCQ 2957/4885GSK3A 2053/4885GSK3B 2206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.